Profile photo Onno Kranenburg

Onno Kranenburg

Full Professor

Biography

Onno Kranenburg received his PhD in 1995 from Leiden University under supervision of Prof Alex van der Eb. After a post-doc in the Netherlands Cancer Institute, he moved to UMC Utrecht where he started his translational studies on the mechanism of action of anti-angiogenic drugs in the group of Prof Emile Voest. In 2003 he became Assistant Professor and PI at the Department of Surgery with Prof Inne Borel Rinkes and started to work on the mechanisms of colon cancer metastasis. In 2006 he became Associate Professor, head of the Surgery Lab and staff member at the Department of Surgery. In 2012 he became coordinator of the PhD research school Clinical and Translational Oncology, which he currently heads as director. In 2015 he was appointed Professor of Surgical and Translational Tumor Biology and founded the Lab Translational Oncology, where he continues to design and test novel strategies for the prevention and treatment of colon cancer metastasis. He also founded and chairs the Utrecht Platform for Organoid Technology, now a central facility in the UMCU that stimulates organoid-based biomedical and clinical research. In recognition of his contribution to tranlational oncology research he was appointed Distinguished Visiting Professor at Tsinghua University in Beijing China, in 2026.

Research groups

Translational oncology

Research aim

To develop, test, and implement novel therapeutic and diagnostic strategies to combat cancer by integrating fundamental and clinical research.

Go to group

Recent publications

Site-dependent treg cell transcriptional reprograming in a metastatic colorectal cancer model holds prognostic significance Sonia Aristin Revilla, Andre Verheem, Cynthia Lisanne Frederiks, Yongsoo Kim, Theofilos Chalkiadakis, Bastiaan J Viergever, Balázs Győrffy, Enric Mocholi, Onno Kranenburg, Stefan Prekovic, Paul James Coffer
Cancer Letters, 2026, vol. 656
Portal vein embolization versus radiation lobectomy as pre-treatment for major liver resection for colorectal liver metastases Khalil Ramdhani, Rosalie C M van Rees, Daan Andel, Jeanine M L Roodhart, Arthur J A T Braat, Rutger C G Bruijnen, Inne H M Borel Rinkes, Onno Kranenburg, Marnix G E H Lam, Maarten L J Smits, Jeroen Hagendoorn
Angiogenesis, 2026, vol. 29
Emergence of oncofetal plasticity is ubiquitous in early colorectal cancers Julian R. Buissant des Amorie, Joris H. Hageman, Sascha R. Brunner, Suzanne E.M. van der Horst, Maria C. Puschhof, Arne van Hoeck, Inge van Lierop, Sjors Middelkamp, Lisa van der Schee, Sven van Kempen, Folkert Morsink, Robin Geene, Sander Mertens, David S. Cavigelli, Ingrid Verlaan-Klink, Lianne J. Kraaier, Jorieke Salij, Renate Bezemer, Onno Kranenburg, Miangela M. Laclé, Leon M.G. Moons, Hugo J.G. Snippert
Nature, 2026, vol. 654, p.229-239
Long-term Survival Outcomes of Synchronous Colon Cancer Eva Rademaker, Bade C Aktas, Petur Snaebjornsson, Johannes H W de Wilt, Niels F M Kok, Esther C J Consten, Pieter J Tanis, Henderik L Van Westreenen, , Helma van Grevenstein, Madelief Kieboom, Onno Kranenburg, Milan Richir, Djurre de Waard
Diseases of the Colon and Rectum, 2026, vol. 69, p.360-373
Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis Fenfen Ji, Pingmei Huang, Qiming Zhou, Lok Hin Ko, Qinyao Wei, Charis Cheuk Lok Chan, Danyu Chen, Huarong Chen, Wei Kang, Alvin Ho Kwan Cheung, Cillian H. Cheng, Jianming Shen, Yasi Pan, Ying Jiao, Lin Zhu, Tat Wai Chik, Peisi Xie, Xiao Liang, Onno Kranenburg, Zongwei Cai, Jun Yu, Chi Chun Wong
Cell Metabolism, 2026, vol. 38, p.794-811.e8
Further characterisation of immortalised human lymphatic endothelial cells to explore their transcriptomic profile and VEGFC response Kazim Ogmen, Ruby Moy, Sara E Dobbins, Lotte van den Bent, Onno Kranenburg, Jeroen Hagendoorn, Alan Pittman, Pia Ostergaard, Silvia Martin-Almedina
Scientific Reports, 2025, vol. 15

Fellowships & Awards

1. KWF2015-8088. Targeting mesenchymal-tyope colon cancer by aggravating oxidative damage. €573.500. 
2. Scope: Modulation of chemotherapy efficacy and toxicity by nutrition in metastatic colorectal cancer. €586.000.
3. ZonMw 2014: PDGF-receptor-targeted therapy for the treatment of poor prognosis mesenchymal-type colon cancer: A window trial. €108.000
4. Gieskes-Strijbis Fonds 2014: The relationship between primary colorectal tumors and their liver metastases: Biological subgroups and therapy response. €290.000
5. Vrienden UMC Utrecht 2013. Title: Targeting colon tumors at their root: Elimination of Cancer Stem Cells. €217.000   
6. KWF UU2011-5226 Title: LIMK1 control of CD95 function in colorectal cancer. €553.300   
7. KWF UU2011-5135. Suppression of LIMK1 by oncogenic KRAS and RAF1: A critical survival pathway in colorectal cancer? €560.000
8. KWF UU2009-4417. The contribution of CD95 signalling to recurrence of colorectal liver metastases following radiofrequency ablation. €592.100   

External positions

Chair - supervision UPORT facility team - Utrecht Platform for Organoid technology